Cargando…

Endocrinology and hormone therapy in breast cancer: Aromatase inhibitors versus antioestrogens

Endocrine therapies act by either blocking or downregulating the oestrogen receptor or by reducing oestrogen concentrations around and within the cancer cell. In postmenopausal women, oestrogen suppression is achieved by inhibition of the enzyme aromatase by aromatase inhibitors (AIs). Modern AIs (a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Howell, Anthony, Dowsett, Mitch
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2004
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1064088/ https://www.ncbi.nlm.nih.gov/pubmed/15535858 http://dx.doi.org/10.1186/bcr945

Ejemplares similares

First-line endocrine treatment of breast cancer: aromatase inhibitor or antioestrogen?
por: Wong, Z-W, et al.
Publicado: (2004)

Non-Steroidal Antioestrogens
por: Barnes, D.
Publicado: (1983)

Combination therapy with aromatase inhibitors: the next era of breast cancer treatment?
por: Leary, A, et al.
Publicado: (2006)

Influence of the antioestrogen tamoxifen on normal breast tissue.
por: Walker, K. J., et al.
Publicado: (1991)

Molecular response to aromatase inhibitor treatment in primary breast cancer
por: Mackay, Alan, et al.
Publicado: (2007)

Endocrinology and hormone therapy in breast cancer: Endocrine therapy in premenopausal women
por: Pritchard, Kathleen
Publicado: (2005)

BCAR4 induces antioestrogen resistance but sensitises breast cancer to lapatinib
por: Godinho, M F E, et al.
Publicado: (2012)

Treatment of breast cancer with aromatase inhibitors--current status and future prospects.
por: LÃ¸nning, P. E., et al.
Publicado: (1989)

Endocrinological and clinical evaluation of exemestane, a new steroidal aromatase inhibitor.
por: Zilembo, N., et al.
Publicado: (1995)

Biological effects of stable overexpression of aromatase in human hormone-dependent breast cancer cells.
por: Macaulay, V. M., et al.
Publicado: (1994)

Parathyroid hormone-related protein secretion is inhibited by oestradiol and stimulated by antioestrogens in KPL-3C human breast cancer cells.
por: Kurebayashi, J., et al.
Publicado: (1997)

Human epidermal growth factor receptor-2 and endocrine resistance in hormone-dependent breast cancer
por: Alataki, Anastasia, et al.
Publicado: (2022)

The what, why and how of aromatase inhibitors: hormonal agents for treatment and prevention of breast cancer
por: Fabian, C J
Publicado: (2007)

Aromatase inhibitor strategies in metastatic breast cancer
por: McArthur, Heather L, et al.
Publicado: (2010)

Clinical utilities of aromatase inhibitors in breast cancer
por: Chumsri, Saranya
Publicado: (2015)

Preventive effects of antioestrogen on mammary and pituitary tumorigenesis in rats.
por: Sumi, C., et al.
Publicado: (1984)

Effects of 4-hydroxytamoxifen and a novel pure antioestrogen (ICI 182780) on the clonogenic growth of human breast cancer cells in vitro.
por: DeFriend, D. J., et al.
Publicado: (1994)

Therapeutic effects of the aromatase inhibitor fadrozole hydrochloride in advanced breast cancer.
por: Bonnefoi, H. R., et al.
Publicado: (1996)

The effect of clodronate and antioestrogens on bone loss associated with oestrogen withdrawal in postmenopausal women with breast cancer
por: Saarto, T, et al.
Publicado: (2001)

Molecular profiling of aromatase inhibitor sensitive and resistant ER+HER2- postmenopausal breast cancers
por: Schuster, Eugene F., et al.
Publicado: (2023)

Molecular characterisation of aromatase inhibitor-resistant advanced breast cancer: the phenotypic effect of ESR1 mutations
por: Lopez-Knowles, Elena, et al.
Publicado: (2018)

Review of hormone-based treatments in postmenopausal patients with advanced breast cancer focusing on aromatase inhibitors and fulvestrant
por: Kümler, Iben, et al.
Publicado: (2016)

Impact of Duration of Neoadjuvant Aromatase Inhibitors on Molecular Expression Profiles in Estrogen Receptor–positive Breast Cancers
por: Bergamino, Milana A., et al.
Publicado: (2022)

Integrative analyses identify modulators of response to neoadjuvant aromatase inhibitors in patients with early breast cancer
por: López-Knowles, Elena, et al.
Publicado: (2015)

Effects of the antioestrogen tamoxifen on the cell cycle kinetics of the human breast cancer cell line, MCF-7.
por: Lykkesfeldt, A. E., et al.
Publicado: (1984)

Clodronate improves bone mineral density in post-menopausal breast cancer patients treated with adjuvant antioestrogens.
por: Saarto, T., et al.
Publicado: (1997)

Role of aromatase inhibitors in breast cancer
por: Carpenter, R, et al.
Publicado: (2005)

Endocrinology and hormone therapy in breast cancer: Selective oestrogen receptor modulators and downregulators for breast cancer – have they lost their way?
por: Johnston, Stephen RD
Publicado: (2005)

Long-term safety of aromatase inhibitors in the treatment of breast cancer
por: Nabholtz, Jean-Marc A
Publicado: (2008)

Update on the use of aromatase inhibitors in early-stage breast cancer
por: Kesisis, Georgios, et al.
Publicado: (2009)

Aromatase Inhibitor-Induced Erythrocytosis in a Patient Undergoing Hormonal Treatment for Breast Cancer
por: Yeruva, Sri Lakshmi Hyndavi, et al.
Publicado: (2015)

Introducing a new section to Breast Cancer Research: Endocrinology and hormone therapy
por: Craig Jordan, V, et al.
Publicado: (2003)

Impact of aromatase inhibitor treatment on global gene expression and its association with antiproliferative response in ER+ breast cancer in postmenopausal patients
por: Gao, Qiong, et al.
Publicado: (2019)

Endocrinology and hormone therapy in breast cancer: New insight into estrogen receptor-α function and its implication for endocrine therapy resistance in breast cancer
por: Schiff, Rachel, et al.
Publicado: (2005)

Clinical translation of progress in molecular endocrinology
por: Dowsett, M
Publicado: (2000)

The potency and clinical efficacy of aromatase inhibitors across the breast cancer continuum
por: Lønning, P. E.
Publicado: (2011)

The Effect of Metalloestrogens on the Effectiveness of Aromatase Inhibitors in a Hormone-Dependent Breast Cancer Cell Model
por: Boszkiewicz, Kamila, et al.
Publicado: (2023)

Long-Term Outcome of Neoadjuvant Endocrine Therapy with Aromatase Inhibitors in Elderly Women with Hormone Receptor-Positive Breast Cancer
por: Grassadonia, Antonino, et al.
Publicado: (2014)

Management of arthralgias associated with aromatase inhibitor therapy
por: Thorne, C.
Publicado: (2007)

Treatment of hormone positive uterine leiomyosarcoma with aromatase inhibitors
por: Thanopoulou, Eirini, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_3li98nderpe93qk77q6h31ob9k